SAB begins phase I trial of COVID-19 treatment
SAB Biotherapeutics has started a phase I trial evaluating SAB-185 for the treatment of COVID-19. Read More
Romark begins phase III trial of COVID-19 antiviral
Romark has initiated a phase III clinical trial of its investigational new drug candidate Nt-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19. Read More
Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio. Read More
Bruker supports COVID19-NMR Consortium
Bruker is highlighting its support of a global project called COVID19-NMR that will investigate the structure, dynamics, function, and binding of SARS-CoV-2 viral RNA and proteins using nuclear magnetic resonance (NMR) spectroscopy. Read More
Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2. Read More
Illumina's Q2 revenue drops 25%
Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also dropped sharply. Read More
Illumina launches affordable sequencing kit for labs
Illumina has launched its NovaSeq 6000 v1.5 reagent kit, intended to make genome sequencing more accessible and affordable for labs of all sizes with the introduction of the "$600 genome." Read More
Pfizer to manufacture remdesivir for Gilead
Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other external manufacturing organizations in supporting efforts to scale up supply for the treatment of COVID-19. Read More
Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's COVID-19 vaccine candidate. Read More
CROs offer new COVID-19 services
Contract research organizations (CROs) Caprion-HistoGeneX and Viroclinics have formed a strategic partnership to develop therapeutics and prophylactic solutions targeting infectious diseases like COVID-19. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
